LENSAR Q2 2026 Earnings Report

LENSAR EPS Results

• Actual EPS: N/A
• Consensus EPS: -$0.17
• Beat/Miss: N/A
• One Year Ago EPS: N/A

LENSAR Revenue Results

• Actual Revenue: N/A
• Expected Revenue: $14.65 million
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

LENSAR Announcement Details

• Quarter: Q2 2026
• Date: 8/6/2026
• Time: Before Market Opens
• Conference Call Date: Thursday, August 6, 2026
• Conference Call Time: 12:30PM ET

LENSAR (NASDAQ:LNSR), headquartered in Orlando, Florida, is a medical technology company specializing in advanced laser systems for ophthalmic surgery. Its flagship product, the LENSAR Laser System, combines proprietary three-dimensional imaging with precision-guided femtosecond laser delivery to perform critical steps in cataract procedures, including capsulotomy creation, lens fragmentation and corneal incisions.

Founded in 2005, LENSAR has concentrated its research and development efforts on enhancing surgical accuracy and patient outcomes in cataract treatment. The company holds multiple patents related to its image-guided treatment planning and laser control algorithms. Clinical collaborations and peer-reviewed studies have supported the safety and efficacy of the LENSAR system, demonstrating improvements in procedural consistency and efficiency.

Operating across North America, Europe, the Asia-Pacific region and Latin America, LENSAR markets its laser platforms to hospitals, ambulatory surgery centers and specialty eye clinics. The company offers comprehensive training programs for ophthalmic surgeons, ongoing technical support and regular software upgrades to help practices integrate femtosecond laser technology. By maintaining a focused portfolio of ophthalmic solutions, LENSAR seeks to advance the standard of care in cataract surgery through continuous innovation and service excellence.